Advertisement

Spiriva Linked to Possible Increased Risk for Stroke, FDA Says — Physician’s First Watch

Medical News |
March 19, 2008

Spiriva Linked to Possible Increased Risk for Stroke, FDA Says

Spiriva HandiHaler (tiotropium bromide), used for treating COPD-associated bronchospasm, may increase the risk for stroke, the FDA says in an early communication.

The manufacturer told the FDA that in 29 placebo-controlled studies, the estimated risk for stroke was 8 cases per 1000 patients treated for 1 year with Spiriva, compared with 6 cases per 1000 receiving a placebo.

The manufacturer, Boehringer Ingelheim, expects safety data from a large, 4-year study to be available in June. The FDA says it will make its recommendations once it has analyzed that data.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement